Effects of dapagliflozin on inflammatory level and prognosis in patients with type 2 diabetes mellitus and acute myocardial infarction
10.12025/j.issn.1008-6358.2025.20250684
- VernacularTitle:达格列净对2型糖尿病合并急性心肌梗死患者炎症水平及预后的影响
- Author:
Mengmei LI
1
;
Weifeng ZHANG
1
;
Xiaowen ZHEN
1
;
Weisheng LIU
1
Author Information
1. Department of Emergency (Chest Pain Center), Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao 266042, Shandong, China.
- Publication Type:Originalarticle
- Keywords:
dapagliflozin;
type 2 diabetes mellitus;
acute myocardial infarction;
inflammatory;
cardiac function
- From:
Chinese Journal of Clinical Medicine
2026;33(1):38-44
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effects of dapagliflozin on inflammatory factors and prognosis in patients with type 2 diabetes mellitus (T2DM) and acute myocardial infarction (AMI). Methods In a randomized, double-blind trial, 146 patients with T2DM and AMI (within 7 days of onset) were divided into dapagliflozin (dapagliflozin 10 mg/d combining AMI standard therapy) and control (AMI standard therapy) groups, and were followed up for 12 months. Serum levels of interleukin-1β (IL-1β), IL-6, high-sensitivity C reactive protein (hs-CRP) at baseline, 1, 3, 6, and 12 months, and left ventricular ejection fraction (LVEF), brain natriuretic peptide (BNP), and major adverse cardiovascular events (MACE) rate at 12 months were compared between the two groups. Kaplan-Meier curves were used to analyze the cumulative incidences of MACE in the two groups. Results Three patients were withdrawn or dropped out. At 12 months, IL-1β, IL-6, and hs-CRP levels were significantly lower in dapagliflozin group (n＝71) than those in control group (n＝72, P＜0.01), approaching normal levels. Compared with the control group, LVEF was higher (P＜0.01), BNP was lower (P＜0.01), MACE incidence was lower (P＝0.047) in dapagliflozin group at 12 months. Generalized linear mixed models showed significant group-time interactions in IL-1β, IL-6, and hs-CRP (P＜0.001), and these factors declined faster in the dapagliflozin group. Kaplan-Meier curve showed the cumulative incidences of MACE and heart failure were lower in dapagliflozin group than those in non-dapagliflozin group (P＜0.05). Conclusions For patients with T2DM patients and AMI, dapagliflozin has good anti-inflammatory and cardioprotective effects.
